What is Aridis Pharmaceuticals?
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm dedicated to the discovery and development of targeted immunotherapies. The company specializes in creating fully human monoclonal antibodies (mAbs) designed to combat severe infections. Its primary product candidate, AR-301, is a fully human IgG1 mAb currently undergoing Phase III pivotal trials for the treatment of Staphylococcus aureus alpha-toxin-induced lung infections. Founded in 2003 and based in Los Gatos, California, Aridis Pharmaceuticals is strategically positioned to address critical unmet medical needs in infectious disease treatment.
How much funding has Aridis Pharmaceuticals raised?
Aridis Pharmaceuticals has raised a total of $6.8M across 3 funding rounds:
Debt
$3.5M
Debt
$3M
Debt
$350K
Debt (2014): $3.5M, investors not publicly disclosed
Debt (2015): $3M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Key Investors in Aridis Pharmaceuticals
PPP
Public-Private Partnership
What's next for Aridis Pharmaceuticals?
The substantial enterprise-level funding and recent strategic investment indicate a strong confidence in Aridis Pharmaceuticals' therapeutic pipeline, particularly AR-301. This capital infusion is expected to fuel the advancement of its Phase III trials and support potential commercialization efforts. The company's focus on fully human monoclonal antibodies for life-threatening infections places it at the forefront of biopharmaceutical innovation, aiming to provide critical solutions in an area with significant global health implications. Future growth will likely involve navigating regulatory pathways and expanding its portfolio of targeted immunotherapies.
See full Aridis Pharmaceuticals company page
